Browse the corpus

REFERENCES Burstein HJ, Prestrud AA, Seidenfeld J, et al, “American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women with Hormone Receptor-Positive Breast Cancer,” J Clin Oncol , 2010, 28(23):3784-96. [PubMed 20625130 ] Buzdar AU, Robertson JF, Eiermann W, et al, “An Overview of the Pharmacology and Pharmacokinetics of the Newer Generation Aromatase Inhibitors Anastrozole, Letrozole, and Exemestane,” Cancer , 2002, 95(9):2006-16. [PubMed 12404296 ] Cuzick J, Sestak I, Baum M, et al, “Effect of Anastrozole and Tamoxifen as Adjuvant Treatment for Early-Stage Breast Cancer: 10-Year Analysis of the ATAC Trial,” Lancet Oncol , 2010, 11(12):1135-41. [PubMed 21087898 ] del Carmen MG, Fuller AF, Matulonis U, et al, “Phase II Trial of Anastrozole in Women With Asymptomatic Müllerian Cancer,” Gynecol Oncol , 2003, 91(3):596-602. [PubMed 14675683 ] Eastell R, Adams JE, Coleman RE, et al, “Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230,” J Clin Oncol , 2008, 26(7):1051-7. [PubMed 18309940 ] Forbes JF, Cuzick J, Buzdar A, et al, “Effect of Anastrozole and Tamoxifen as Adjuvant Treatment for Early-Stage Breast Cancer: 100-month Analysis of the ATAC Trial,” Lancet Oncol , 2008, 9(1):45-53. [PubMed 18083636 ] Jenkins VA, Ambroisine LM, Atkins L, et al, “Effects of Anastrozole on Cognitive Performance in Postmenopausal Women: A Randomised, Double-Blind Chemoprevention Trial (IBIS II),” Lancet Oncol , 2008, 9(10):953-61. [PubMed 18768369 ] Kaufmann M, Jonat W, Hilfrich J, et al, “Improved Overall Survival in Postmenopausal Women With Early Breast Cancer After Anastrozole Initiated After Treatment With Tamoxifen Compared With Continued Tamoxifen: The ARNO 95 Study,” J Clin Oncol , 2007, 25(19):2664-70. [PubMed 17563395 ] Kendall A, Dowsett M, Folkerd E, et al, “Caution: Vaginal Estradiol Appears to be Contraindicated in Postmenopausal Women on Adjuvant Aromatase Inhibitors,” Ann Oncol , 2006, 17(4):584-7. [PubMed 16443612 ] Koberle D and Thurlimann B, “Anastrozole: Pharmacological and Clinical Profile in Postmenopausal Women With Breast Cancer,” Expert Rev Anticancer Ther , 2001, 1(2):169-76. [PubMed 12113022 ]

Kendall A, Dowsett M, Folkerd E, et al, “Caution: Vaginal Estradiol Appears to be Contraindicated in Postmenopausal Women on Adjuvant Aromatase Inhibitors,” Ann Oncol , 2006, 17(4):584-7. [PubMed 16443612 ] Koberle D and Thurlimann B, “Anastrozole: Pharmacological and Clinical Profile in Postmenopausal Women With Breast Cancer,” Expert Rev Anticancer Ther , 2001, 1(2):169-76. [PubMed 12113022 ] Lester JE, Dodwell D, Purohit OP, et al, “Prevention of Anastrozole-Induced Bone Loss With Monthly Oral Ibandronate During Adjuvant Aromatase Inhibitor Therapy for Breast Cancer,” Clin Cancer Res , 2008, 14(19):6336-42. [PubMed 18829518 ] Lonning PE, Geisler J, and Dowsett M, “Pharmacological and Clinical Profile of Anastrozole,” Breast Cancer Res Treat , 1998, 49(Suppl 1):53-7. Lonning P, Pfister C, Martoni A, et al, “Pharmacokinetics of Third-Generation Aromatase Inhibitors,” Semin Oncol , 2003, 30(4 Suppl 14):23-32. [PubMed 14513434 ] National Comprehensive Cancer Network® (NCCN), “Clinical Practice Guidelines in Oncology™: Breast Cancer,” Version 3.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/breast.pdf National Comprehensive Cancer Network® (NCCN), “Clinical Practice Guidelines in Oncology™: Ovarian Cancer,” Version 1.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf National Comprehensive Cancer Network® (NCCN), “Clinical Practice Guidelines in Oncology™: Uterine Neoplasms,” Version 1.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/uterine.pdf National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. National Osteoporosis Foundation, “Clinician's Guide to Prevention and Treatment of Osteoporosis,” Washington, DC, 2010. Available at file://www.nof.org/files/nof/public/content/file/344/upload/159.pdf Njar VC and Brodie AM, “Comprehensive Pharmacology and Clinical Efficacy of Aromatase Inhibitors,” Drugs , 1999, 58(2):233-55. [PubMed 10473018 ] Rose PG, Brunetto VL, VanLe L, et al, “A Phase II Trial of Anastrozole in Advanced Recurrent or Persistent Endometrial Carcinoma: A Gynecologic Oncology Group Study,” Gynecol Oncol , 2000, 78(2):212-6. [PubMed 10926805 ]

Njar VC and Brodie AM, “Comprehensive Pharmacology and Clinical Efficacy of Aromatase Inhibitors,” Drugs , 1999, 58(2):233-55. [PubMed 10473018 ] Rose PG, Brunetto VL, VanLe L, et al, “A Phase II Trial of Anastrozole in Advanced Recurrent or Persistent Endometrial Carcinoma: A Gynecologic Oncology Group Study,” Gynecol Oncol , 2000, 78(2):212-6. [PubMed 10926805 ] “Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report,” Circulation , 2002, 106(25):3143-21. [PubMed 12485966 ] Winer EP, Hudis C, Burstein HJ, et al, “American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004,” J Clin Oncol , 2005, 23(3):619-29. [PubMed 15545664 ] Topic 8780 Version 42.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [1104-183.166.191.243-4563C940AB-S244013.14]